Executive Roundtable

Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.

Five industry experts discuss labeling challenges and trends in modernization.

Join five industry leaders as they unpack the transformative potential of artificial intelligence in the pharmaceutical industry, offering insights into real-world applications and the future of life sciences marketing in an era shaped by rapid technological evolution.

Marketing leaders discuss the powerful role life sciences companies can play in the expanding digital landscape for healthcare communications—as “one of the helpful voices” in driving the customer and patient conversations that matter most.

Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.

Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.

Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences—where the common thread seems clear: the messenger matters.

Biopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation.

Our latest CEO Leadership roundtable focused on the most top-of-mind issues for companies.

Chief commercial officers gather for an insightful roundtable discussion anchored in the future of sales and marketing in light of new communication media brought on by the pandemic.

Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.

A panel of pharma digital leaders discusses pathways for technology and data scale-up—and the skills, mindset, and C-suite influence needed to drive true digital transformation.

In this roundtable discussion, Steve Gens, Remco Munnik and James Kelleher explore the potential and the practicalities of building future processes on a single, joined-up content platform.

Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.

Recent roundtable brought together by Pharm Exec and Parexel features insights from leaders in the pharma industry on the current state and future of RWE.

Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.

A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.

A recent roundtable moderated by Dr. Scott Gottlieb gathered biopharma CEOs to share thoughts and strategies on navigating their companies through the COVID-19 outbreak.

Pharm Exec sits down with a pair of big pharma compliance leaders to discuss the strategic move to principles-based policies and the impact of other emerging forces influencing industry compliance practice.

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today-how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.

Pharm Exec convenes a roundtable discussion with several company chief information officers (CIOs) and IMS Health to explore ways to turn the vast reams of data now being generated in the transactional tsunami of modern healthcare into truly meaningful insights for its users.

Experts from industry and academia probe the changing role of the pharmacoepidemiology function as it grapples with the challenges of big data analytics, tightening drug safety requirements, growing post-approval study burdens, and payer expectations around the application of real-world evidence.

In a knowledge industry like biopharma, people are the intangible asset that marks the difference between a status quo or standout performance. Pharm Exec recently convened a panel of industry team leaders and HR specialists at St. Joseph’s University Haub School of Business to parse out some useful best practices in three key areas: talent recruitment and retention; skills training; and workforce diversity.

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.